Inventor · disambiguated record
Lida Tehrani
Also filed as: TEHRANI LIDA · TEHRANI LIDA R · TEHRANI LIDA RADNIA
25 granted patents·7 pending applications·362 citations·filing 2002–2024
96Inventor score
Files withCELGENE CORP9SIGNAL PHARM LLC7MERCK & CO INC5PERRIN-NINKOVIC SOPHIE3SIGNAL PHARMACEUTICAL LLC3
Top patents by PatentIndex Score
32 records- 0198US7981893B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jul 19, 2011·90 cites·10 claims
- 0296US11634407B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Apr 25, 2023·5 cites·66 claims
- 0396US8492381B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Jul 23, 2013·44 cites·21 claims
- 0496US8110578B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2009·Granted Feb 7, 2012·67 cites·28 claims
- 0595US8372976B2Methods of treatment comprising the administration of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2011·Granted Feb 12, 2013·40 cites·1 claims
- 0693US11739075B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Aug 29, 2023·3 cites·17 claims
- 0793US11560371B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 24, 2023·3 cites·18 claims
- 0893US8507492B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Aug 13, 2013·22 cites·20 claims
- 0988US9771371B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2015·Granted Sep 26, 2017·4 cites·6 claims
- 1087US8299056B2Aminotriazolopyridines, compositions thereof, and methods of treatment therewithBAHMANYAR SOGOLE·Filed 2009·Granted Oct 30, 2012·22 cites·31 claims
- 1186US7462619B2Pyridazine, pyrimidine and pyrazine ethyne compoundsMERCK & CO INC·Filed 2005·Granted Dec 9, 2008·5 cites·2 claims
- 1285US7750151B2Inhibitors of Akt activityMERCK SHARP & DOHME·Filed 2005·Granted Jul 6, 2010·10 cites·2 claims
- 1383US9428509B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted Aug 30, 2016·6 cites·32 claims
- 1483US9346812B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted May 24, 2016·6 cites·30 claims
- 1581US7105548B2Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5MERCK & CO INC·Filed 2002·Granted Sep 12, 2006·15 cites·6 claims
- 1680US10167290B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2017·Granted Jan 1, 2019·1 cites·5 claims
- 1780US2023119470A1PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAYSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 1878US2025188056A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 1977US7910561B2Inhibitors of Akt activityMERCK SHARP & DOHME·Filed 2005·Granted Mar 22, 2011·3 cites·4 claims
- 2076US12103920B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Oct 1, 2024·0 cites·15 claims
- 2176US7268151B2Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5MERCK & CO INC·Filed 2004·Granted Sep 11, 2007·10 cites·6 claims
- 2274US11292796B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2020·Granted Apr 5, 2022·0 cites·5 claims
- 2373US7365074B2Pyridazine, pyrimidine and pyrazine ethyne compoundsMERCK & CO INC·Filed 2004·Granted Apr 29, 2008·5 cites·2 claims
- 2472US12227490B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Feb 18, 2025·0 cites·18 claims
- 2572US10683298B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2018·Granted Jun 16, 2020·0 cites·8 claims
- 2662US7393959B2Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5MERCK & CO INC·Filed 2004·Granted Jul 1, 2008·1 cites·6 claims
- 2761US2025100995A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 2859US2024368118A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 2959US2024374591A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 3053US9795607B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2016·Granted Oct 24, 2017·0 cites·33 claims
- 3143US2013005707A1Aminotriazolopyridines, compositions thereof, and methods of treatment therewithBAHMANYAR SOGOLE·Filed 2012·Application pending·0 cites
- 3238US2006194807A1Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5COSFORD NICHOLAS D P·Filed 2004·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →